Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Relative Risk01:12

Relative Risk

2.5K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.5K
Hazard Ratio01:12

Hazard Ratio

752
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
752
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

415
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
415
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

407
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
407
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How variants of uncertain significance affect clinical decisions: A systematic review.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Stakeholder views about the responsibilities of principal investigators in multicenter randomized controlled trials.

Clinical trials (London, England)·2026
Same author

Response to Sansom et al.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

JCO precision oncology·2025
Same author

The ethics of heritable human genome editing.

Fertility and sterility·2025
Same author

Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies.

JAMA network open·2025
Same journal

A Study of Reliance Agreement Templates Used by U.S. Research Institutions.

IRB·2021
Same journal

Reasonable Research Oversight: A Work in Progress.

IRB·2019
Same journal

The Revised and Final Common Rule: An Unfinished Story.

IRB·2019
Same journal

Reining in IRB Review in the Revised Common Rule.

IRB·2019
Same journal

On Improving Oversight and Enhancing Protections.

IRB·2019
Same journal

Understanding, Therapeutic Misconceptions and Perceptions, and Enrollment Decision-Making: A Pediatric Preventive Malaria Trial in Rural Tanzania.

IRB·2019
See all related articles

Related Experiment Video

Updated: Apr 27, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Determining minimal risk for comparative effectiveness research

Steven Joffe, Alan Wertheimer

    IRB
    |June 21, 2014
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    An R-Based Landscape Validation of a Competing Risk Model
    05:37

    An R-Based Landscape Validation of a Competing Risk Model

    Published on: September 16, 2022

    2.3K
    Establishing a Competing Risk Regression Nomogram Model for Survival Data
    04:57

    Establishing a Competing Risk Regression Nomogram Model for Survival Data

    Published on: October 23, 2020

    9.9K

    Related Experiment Videos

    Last Updated: Apr 27, 2026

    Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
    06:55

    Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

    Published on: January 8, 2020

    14.3K
    An R-Based Landscape Validation of a Competing Risk Model
    05:37

    An R-Based Landscape Validation of a Competing Risk Model

    Published on: September 16, 2022

    2.3K
    Establishing a Competing Risk Regression Nomogram Model for Survival Data
    04:57

    Establishing a Competing Risk Regression Nomogram Model for Survival Data

    Published on: October 23, 2020

    9.9K